Agios Pharmaceuticals

Agios Pharmaceuticals, Inc.
Public
Traded as NASDAQ: AGIO
Industry Pharmaceuticals
Founded 2008 (2008)
Headquarters Cambridge, Massachusetts, United States
Key people
 David Schenkein (CEO, 2012)
Website agios.com
Footnotes / references
Foundation[1]

Agios Pharmaceuticals is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway.[1][2] Among the proteins under investigation by the company are IDH1 and IDH2.[3] The company was founded in 2008 (or 2007)[3] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[1][4] The company tendered an initial public offering in July 2013.[5]:Table 1

In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.[3]

In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies. The deal could net more than $1 billion for Agios.[6]

Corporate governance

As of February 2012, Agios' CEO was David Schenkein.[3]

Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.[3][5]

References

  1. 1 2 3 Pfeffer, Cary G. (2012). "The biotechnology sector". In Burns, Lawton R. The Business of Healthcare Innovation (Google eBook). Cambridge, United Kingdom: Cambridge University Press. pp. 224, 228. ISBN 9781107024977.
  2. ↑ Anton, Ted (2013). "Chapter 13". The Longevity Seekers (Google eBook). University of Chicago Press. p. 163. ISBN 9780226020938.
  3. 1 2 3 4 5 Pollack, Andrew (February 5, 2012). "Sloan-Kettering Chief Is Accused of Taking Research". The New York Times.
  4. ↑ "AGIOS PHARMACEUTICALS, INC.". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 18, 2014. Commission File Number:001-36014.
  5. 1 2 Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71.
  6. ↑ "Celgene, Agios, Launch $1B+ Metabolic Immuno-oncology Alliance - GEN News Highlights - GEN". GEN.

Notes


    This article is issued from Wikipedia - version of the 10/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.